SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Paludan Merete)
 

Search: WFRF:(Paludan Merete) > (2008) > Stereotactic body r...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Baumann, PiaKarolinska Institutet,Divisions of Oncology, Hospital Physics, Radiumhemment, Sweden (author)

Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • Elsevier BV,2008

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/100357
  • https://gup.ub.gu.se/publication/100357URI
  • https://doi.org/10.1016/j.radonc.2008.07.019DOI
  • https://lup.lub.lu.se/record/1284130URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-105474URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:117783253URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-50265URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND AND AIMS: In a retrospective study using stereotactic body radiotherapy (SBRT) in medically inoperable patients with stage I NSCLC we previously reported a local control rate of 88% utilizing a median dose of 15Gyx3. This report records the toxicity encountered in a prospective phase II trial, and its relation to coexisting chronic obstructive pulmonary disease (COPD) and cardio vascular disease (CVD). MATERIAL AND METHODS: Sixty patients were entered in the study between August 2003 and September 2005. Fifty-seven patients (T1 65%, T2 35%) with a median age of 75 years (59-87 years) were evaluable. The baseline mean FEV1% was 64% and median Karnofsky index was 80. A total dose of 45Gy was delivered in three fractions at the 67% isodose of the PTV. Clinical, pulmonary and radiological evaluations were made at 6 weeks, 3, 6, 9, 12, 18, and 36 months post-SBRT. Toxicity was graded according to CTC v2.0 and performance status was graded according to the Karnofsky scale. RESULTS: At a median follow-up of 23 months, 2 patients had relapsed locally. No grade 4 or 5 toxicity was reported. Grade 3 toxicity was seen in 12 patients (21%). There was no significant decline of FEV1% during follow-up. Low grade pneumonitis developed to the same extent in the CVD 3/17 (18%) and COPD 7/40 (18%) groups. The incidence of fibrosis was 9/17 (53%) and pleural effusions was 8/17 (47%) in the CVD group compared with 13/40 (33%) and 5/40 (13%) in the COPD group. CONCLUSION: SBRT for stage I NSCLC patients who are medically inoperable because of COPD and CVD results in a favourable local control rate with a low incidence of grade 3 and no grade 4 or 5 toxicity.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Nyman, Jan,1956Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences,Department of Oncology and Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden(Swepub:gu)xnymja (author)
  • Hoyer, MortenDivisions of Oncology and Medical Physics, Aarhus University Hospital, Denmark (author)
  • Gagliardi, GiovannaKarolinska Institutet,Divisions of Oncology, Hospital Physics, Radiumhemment, Sweden (author)
  • Lax, IngmarKarolinska Institutet,Divisions of Oncology, Hospital Physics, Radiumhemment, Sweden (author)
  • Wennberg, BeritKarolinska Institutet,Divisions of Oncology, Hospital Physics, Radiumhemment, Sweden (author)
  • Drugge, NinniGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences,Department of Oncology and Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden (author)
  • Ekberg, LarsDivisions of Oncology, Hospital Physics, Malmö University Hospital, Sweden (author)
  • Friesland, SigneKarolinska Institutet,Divisions of Oncology, Hospital Physics, Radiumhemment, Sweden (author)
  • Johansson, Karl-AxelGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences,Department of Oncology and Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden (author)
  • Lund, Jo-Smund (author)
  • Morhed, ElisabethDepartment of Oncology and Radiotherapy, Akademiska University Hospital, Uppsala, Sweden (author)
  • Nilsson, KristinaUppsala universitet,Enheten för onkologi,Department of Oncology and Radiotherapy, Akademiska University Hospital, Uppsala, Sweden(Swepub:uu)kristnil (author)
  • Levin, NinaDepartment of Oncology, Trondheim University Hospital, Norway (author)
  • Paludan, MereteDivisions of Oncology and Medical Physics, Aarhus University Hospital, Denmark (author)
  • Sederholm, ChristerÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Lungmedicin,Lungmedicinska kliniken US(Swepub:liu)chrse81 (author)
  • Traberg, AndersDivisions of Oncology and Medical Physics, Aarhus University Hospital, Denmark (author)
  • Wittgren, LenaLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine,Divisions of Oncology, Hospital Physics, Malmö University Hospital, Sweden(Swepub:lu)rfa-lwi (author)
  • Lewensohn, RolfKarolinska Institutet,Divisions of Oncology, Hospital Physics, Radiumhemment, Sweden (author)
  • Lund, JALund, J.-Å., Department of Oncology, Trondheim University Hospital, Norway (author)
  • Karolinska InstitutetDivisions of Oncology, Hospital Physics, Radiumhemment, Sweden (creator_code:org_t)

Related titles

  • In:Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology: Elsevier BV88:3, s. 359-670167-81401879-0887

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view